Tjalma or pseudo-pseudo Meigs' syndrome is a clinical condition that is characterized with ascites, pleural effusion, and increased serum CA-125 levels in patients with systemic lupus erythematosus (SLE) without the presence of ovarian tumor. On the other hand, Meigs' and pseudo-Meigs' syndromes represent the same manifestations with ovarian tumor. In this case report, we present a 43-year-old SLE patient suffering from Tjalma syndrome with the coexistence of incidental ovarian teratoma, who was successfully treated with intravenous immunoglobulin-G adjunctive therapy after inadequate response to surgical excision of the ovarian tumor, steroid, and cyclophosphamide pulse therapy.
Introduction
Meigs' and pseudo-Meigs' syndromes are paraneoplastic conditions characterized by ascites, pleural effusion, and increased CA-125 serum levels accompanied by ovarian tumor with resolution of the ascites and hydrothorax after removal of the ovarian lesion (1, 2) . Meigs' syndrome is associated with benign ovarian fibromas (1) . On the other hand, pseudo-Meigs' syndrome occurs in the presence of ovarian teratoma, ovarian carcinoma or leiomyoma. In patients with systemic lupus erythematosus (SLE), there is a similar condition referred to as Tjalma or pseudo-pseudo Meigs' syndrome, which has the systemic manifestations of Meigs' syndrome, but occurs in the absence of an ovarian neoplasm (3) . To date, 6 cases of Tjalma syndrome have been reported and immunosuppressive therapy was shown to effectively treat all of these cases (3) (4) (5) (6) (7) (8) . However, there are few reports of the coexistence of an incidental ovarian tumor with the efficacy of intravenous immunoglobulin-G (IVIG) adjunctive therapy refractory to conventional therapy in Tjalma syndrome.
Here, we present a case of Tjalma syndrome coincidentally accompanied by an ovarian teratoma that was successfully treated with IVIG adjunctive therapy.
Case Report
A 43-year-old woman was admitted to our academic rheumatology clinic with complaints of generalized edema, facial rash, and arthralgia lasting for 5 months. She also complained of abdominal distension, a weight gain of 4 kg over 1 month, and generalized weakness. On physical examination, prominent ascites, bilateral pitting edema of the lower extremities, and swelling of proximal interphalangeal joints were detected. Dermatological examination revealed an erythematous malar rash. Abdominal and pelvic computed tomography (CT) scanning showed a 3.6-cm left ovarian teratoma, uterine myoma, and ascites ( Figure 2 ). However, no definite peritoneal or bowel wall thickening or liver cirrhosis, which can cause ascites, was noted. A blood interferon gamma release assay was negative.
No abnormality was found on colonoscopy and gastroscopy.
Ascitic fluid analysis showed a WBC of 105/mm 3 (2% neutrophils, 34% lymphocytes, and 64% other cells) and CA-125 levels of 302.2 U/mL; the ADA range was normal, and staining and cultures for AFB were negative. Cytologic examination of the ascitic fluid was negative for malignancy and the serum-to-ascites albumin gradient was 0.6 g/dL. On echocardiography, her ejection fraction was 65% and there was no abnormality except for mild eccentric mitral regurgitation.
Fecal alpha-1 antitrypsin (AAT) clearance was 24.7 mL/day, which was within the normal range.
As the patient had left ovarian teratoma, ascites, pleural effusion, and increased serum and ascites CA-125 levels, we initially suspected pseudo-Meigs' syndrome incidentally accompanied by SLE. She consulted a gynecologist for removal of the ovarian teratoma in order to clarify her diagnosis. However, the operation was postponed because of her general medical problems including hypoalbuminemia and ascites. Medical treatment was started with prednisolone at 0.5 mgㆍkg
, 400 mg of hydroxychloroquine for SLE, and diuretics for as- cites and pleural effusion. She was discharged on day 22 and medications were maintained in the outpatient department. Her symptoms had not worsened for about 2 months.
Ninety-eight days after her first visit to our clinic (day 98), the patient was readmitted because her peripheral pitting edema had worsened with an additional weight gain of 5 kg.
Furthermore, dyspnea had newly developed. A follow-up CT scan showed increased ascites and pleural effusion, and her serum CA-125 levels had increased to 2,266 U/mL (Table 1) .
Left salphingo-oophorectomy and uterine myomectomy were performed on day 102. A mature teratoma was diagnosed on pathologic examination of the ovarian specimen. Despite elimination of the ovarian tumor, her pleural effusion and ascites did not resolve, and serum CA-125 levels further increased to 2,951 U/mL on day 141 (Table 1) . Thus, we assumed that persistent pleural effusion and ascites and increased levels of CA-125 were not caused by the teratoma (pseudo-Meigs' syndrome) but by an autoimmune disease such as SLE (Tjalma syndrome). Thereafter, pulse methylprednisolone therapy on 3
consecutive days given as a 1g intravenous bolus followed by oral prednisolone at 1 mgㆍkg -1 ㆍday -1 was started on day 143. However, her ascites and pleural effusion persisted.
Subsequently, on day 148, pulse therapy with 750 mg of cyclophosphamide was added, but her ascites and hypoalbuminemia worsened (Table 1) . Thus, we thought that the patient was refractory to this cytotoxic agent and recommend additional treatment. But, she firmly refused other immunosuppressive agents such as mycophenolate mofetil or azathioprine due to fear of adverse events. Based on previous reports of favorable response of various autoimmune conditions to IVIG, therapy with IVIG was discussed with the patient. Her serum IgA levels were 216.3 mg/dL (normal range 70∼400 mg/dL); after obtaining the patient's consent, an IVIG infusion (2 g/kg over 5 consecutive days) was performed on day 156. After IVIG administration, her pleural effusion and ascites dramatically resolved. In addition, serum albumin levels increased to 4.2 g/dL, and serum CA-125 levels normalized to 33 U/mL on day 197 (Table 1) . Since the IVIG infusion, she has remained in remission and is being followed up in the outpatient department maintaining low dose prednisolone (2.5 mg/day) and hydroxychloroquine only.
Discussion
We believe that this report represents a case of Tjalma syn- (12) . IVIG also showed anti-VEGF antibody activity via stimulating the production of IL-12 which has an anti-angiogenic cytokine and inhibiting VEGF mRNA expression (13) . We speculated that anti-VEGF antibody activity of IVIG would play a role in our patient, considering that VEGF can stimulate CA-125 expression.
Summary
In conclusion, this case suggests that the combination of ascites, pleural effusion, and elevated CA-125 in patients with SLE should indicate the possibility of Tjalma syndrome, even in the presence of ovarian tumor. Additionally, IVIG adjunctive therapy can be effective for the management of Tjalma syndrome.
